Eledon Pharmaceuticals, Inc. (ELDN)
3.41
-0.04
(-1.16%)
USD |
NASDAQ |
Aug 24, 16:00
3.40
-0.01
(-0.29%)
After-Hours: 05:50
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 275.84M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 31.15% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 8.355 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0065 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 99.05% |
Profile
| Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The firm also focuses on development of therapy to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L), a biological target with broad therapeutic potential. The company was founded on March 26, 2004 and is headquartered in Irvine, CA. |
| URL | http://eledon.com |
| Investor Relations URL | https://ir.eledon.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 13, 2026 (est.) |
| Last Earnings Release | Aug. 13, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company, which engages in development of therapies to protect transplanted organs and prevent rejection. The firm also focuses on development of therapy to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L), a biological target with broad therapeutic potential. The company was founded on March 26, 2004 and is headquartered in Irvine, CA. |
| URL | http://eledon.com |
| Investor Relations URL | https://ir.eledon.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 13, 2026 (est.) |
| Last Earnings Release | Aug. 13, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |